Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 8/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28317675 | 0.81 | TXNRD1 (0.51) | VCAM1HSD17B10MAPTTXNRD1TXNRD3 | |
| SCHEMBL11673035 | 0.81 | TDP1 (0.55) | VCAM1MAPTPDE7ATXNRD1TXNRD3 | |
| SCHEMBL5024770 | 0.80 | HSD17B10 (0.64) | VCAM1HSD17B10PDE7APDE4BPDE4D | |
| SCHEMBL30388476 | 0.80 | HSD17B10 (0.64) | VCAM1HSD17B10PDE7APDE4BPDE4D | |
| SCHEMBL466008 | 0.78 | TXNRD1 (0.66) | MAPTTXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL29350780 | 0.78 | TXNRD1 (0.66) | MAPTTXNRD1TXNRD3TXNRD2KMT2A | |
| SCHEMBL11526594 | 0.78 | VCAM1 (0.44) | VCAM1HSD17B10MAPTPDE7APDE4B | |
| SCHEMBL5024771 | 0.77 | HSD17B10 (0.60) | VCAM1HSD17B10PDE7APDE4BPDE4D | |
| SCHEMBL927819 | 0.77 | HSD17B10 (0.60) | VCAM1HSD17B10PDE7APDE4BPDE4D | |
| SCHEMBL19625104 | 0.77 | HSD17B10 (0.60) | VCAM1HSD17B10PDE7APDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| US-7875609-B2 | 3-(4-chlorophenyl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea; treatment of the cancer of the parathyroid and the digestive tract; osteoporosis, osteopaenia and Paget's disease, rheumatoid arthritis and osteoarthritis | GALAPAGOS SASU (FR) | 2011-01-25 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1965805-B1 | UREA DERIVATIVES USEFUL AS CALCIUM RECEPTOR MODULATORS | GALAPAGOS SAS (FR) | 2009-12-02 | — | — | EP | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | PROSKELIA SAS. (FR) | 2007-08-02 | — | — | US | disclosed |
| US-7138075-B2 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20040007695-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-01-15 | — | — | US | disclosed |
| WO-2003101955-A2 | MOLECULAR ACTUATORS, AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | NOD2, PIEZO1, TPR | VCAM1 2836/4885HSD17B10 4759/4885MAPT 3809/4885 |
| US-20070179134-A1 | Urea derivatives, processes for their preparation, their use as medicaments, and pharmaceutical compositions containing them | UTS2R, CACNA1A, CACNA1E | VCAM1 4651/4885HSD17B10 4602/4885MAPT 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.